| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CTNNBIP1 |
| Uniprot No | Q9NSA3 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-81aa |
| 氨基酸序列 | MNREGAPGKSPEEMYIQQKVRVLLMLRKMGSNLTASEEEFLRTYAGVVNSQLSQLPPHSIDQGAEDVVMAFSRSETEDRRQ |
| 预测分子量 | 36.2kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CTNNBIP1重组蛋白的3篇参考文献及其摘要内容：
---
1. **文献名称**：*CTNNBIP1 inhibits β-catenin signaling by reducing its nuclear transport via interaction with importin β*
**作者**：Chen X, et al.
**摘要**：该研究通过重组CTNNBIP1蛋白实验，揭示其通过结合核转运蛋白importin β，抑制β-catenin的核内转运，从而下调Wnt/β-catenin信号通路活性，可能为癌症治疗提供新靶点。
---
2. **文献名称**：*Recombinant CTNNBIP1 disrupts epithelial-mesenchymal transition by targeting β-catenin in hepatocellular carcinoma*
**作者**：Wang Y, et al.
**摘要**：作者利用重组CTNNBIP1蛋白验证其与β-catenin的直接结合，证明其能抑制肝癌细胞的EMT进程，降低肿瘤侵袭性，为肝癌的靶向治疗提供实验依据。
---
3. **文献名称**：*Structural characterization of CTNNBIP1 and its interaction with β-catenin using recombinant protein technology*
**作者**：Li H, et al.
**摘要**：通过重组CTNNBIP1蛋白的晶体结构解析，阐明其与β-catenin结合的分子机制，发现特定结构域对抑制Wnt通路至关重要，为开发小分子抑制剂奠定基础。
---
**备注**：上述文献为示例，实际研究中建议通过PubMed或Google Scholar以“CTNNBIP1 recombinant protein”为关键词检索最新论文。
**Background of CTNNBIP1 Recombinant Protein**
CTNNBIP1 (Catenin Beta Interacting Protein 1), also known as ICAT (Inhibitor of β-catenin and TCF), is a nuclear protein that functions as a key regulator of the Wnt/β-catenin signaling pathway. This pathway plays a critical role in embryonic development, tissue homeostasis, and cell proliferation, with dysregulation linked to cancers and other diseases. CTNNBIP1 inhibits Wnt signaling by binding to the C-terminal transactivation domain of β-catenin, thereby disrupting its interaction with transcription factors TCF/LEF and suppressing target gene expression.
The recombinant CTNNBIP1 protein is engineered to study its molecular interactions and therapeutic potential. Produced via heterologous expression systems (e.g., *E. coli* or mammalian cells), the recombinant form retains functional domains necessary for β-catenin binding, allowing researchers to explore mechanisms of Wnt pathway modulation. It is widely used in *in vitro* assays, such as co-immunoprecipitation, luciferase reporter assays, and structural studies, to dissect its inhibitory effects on oncogenic β-catenin activity.
Studies suggest CTNNBIP1 may act as a tumor suppressor, and its downregulation is observed in colorectal, hepatocellular, and breast cancers. Recombinant CTNNBIP1 also serves as a tool for screening small molecules aimed at restoring Wnt pathway regulation. Additionally, it aids in understanding developmental disorders and tissue regeneration processes influenced by β-catenin dynamics. Its role in balancing cell differentiation and proliferation highlights its relevance in both basic research and therapeutic development.
×
